Gastroenterology

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Conditions: Obesity; Overweight

Interventions: Drug: Eloralintide; Drug: Placebo; Drug: Acetaminophen

Sponsors: Eli Lilly and Company

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 1, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
IKS04 Regimen in Advanced Solid Tumors That Express CA242
Conditions: Colorectal Cancer; Gastro Esophageal Junctional Cancer; Gastric Cancer (GC); GEJ Adenocarcinoma; PDAC – Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancer (BTC); Gall Bladder Cancer; Cholangiocarcinoma

Interventions: Drug: IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody

Sponsors: Iksuda Therapeutics Ltd.

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 1, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
Conditions: Gastric Cancer; Esophageal Cancer

Interventions: Drug: oxaliplatin, capecitabine

Sponsors: University of Southern California; Sanofi; Roche Global Development; Bristol-Myers Squibb

Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 31, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Conditions: Breast Cancer; Non-small Cell Lung Cancer (NSCLC); Gastric/Gastroesophageal Junction (GEJ) Cancer; Bladder Cancer

Interventions: Diagnostic Test: [68Ga]Ga-DWJ155; Drug: [177Lu]Lu-DWJ155

Sponsors: Novartis Pharmaceuticals

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 29, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
Evaluating Whether a Nausea Band Reduces Symptoms in Those With Chronic Nausea Vomiting
Conditions: Chronic Nausea; Chronic Nausea and Vomiting Syndrome

Interventions: Device: EmeTerm wearable TENS device

Sponsors: Ohio State University

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 23, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
Virtual Poetry Workshops to Enhance Patient Well Being and Reduce Anxiety
Conditions: Dyspepsia; Gastroparesis; Anxiety; Depression

Interventions: Behavioral: Poetry; Behavioral: Poetry Manual

Sponsors: Ohio State University

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 22, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
DBC-664 in Adult Patients With Solid Tumors Associated
Conditions: Malignant Germ Cell Tumor; Lung Adenocarcinoma; Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma; Urothelial Carcinoma; Endometrial Adenocarcinoma; Ovarian Adenocarcinoma

Interventions: Biological: DBC-664

Sponsors: Duboce Biopharmaceuticals, Inc.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 16, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer
Conditions: Gastro-esophageal Junction (GEJ) Cancer; Esophagus Cancer

Interventions: Radiation: PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy; Drug: FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)

Sponsors: University of Texas Southwestern Medical Center

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 15, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Conditions: Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Cadonilimab; Drug: CAPOX regimen; Drug: Nivolumab; Drug: Placebo

Sponsors: Akeso

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 15, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Conditions: HER2-negative; Gastroesophageal Junction; Esophageal Adenocarcinoma; Gastric Adenocarcinoma

Interventions: Drug: Denikitug; Drug: Nivolumab; Drug: Ramucirumab; Drug: Paclitaxel

Sponsors: Gilead Sciences

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 11, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Read more 
Free Clinical Trial Updates

    #1 Best New Product in 2019
    Headache Relief Shampoo Banner Ad
    Search For Clinical Trials
      CLOSE
      Please click to geolocate button to change this value.
      SEARCHRESET
      Featured Research Centers